EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
Total income for the period stood at Rs. 7101.28 crore
The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
The observations are procedural in nature and will be responded to within the stipulated time
Diversifying its portfolio to include late-phase antiviral agent
This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
Fenebrutinib targets cells in the immune system known as B cells and microglia
Subscribe To Our Newsletter & Stay Updated